Recursion (NASDAQ: RXRX) CFO granted RSUs, 11,400 shares withheld for taxes

Rhea-AI Filing Summary

Recursion Pharmaceuticals’ Chief Financial Officer Ben R. Taylor reported equity compensation activity. On February 6, 2026, he received 446,279 Class A RSUs that vest in equal sixteenth installments starting May 15, 2026 and every three months afterward, plus 24,254 RSUs that vested immediately.

The company also withheld 11,400 shares at $3.98 per share to satisfy tax obligations from RSU settlement. After these transactions, Taylor directly beneficially owned 1,220,683 shares of Class A Common Stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Taylor Ben R

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	446,279	$0.00	--
Grant/Award	Class A Common Stock	24,254	$0.00	--
Tax Withholding	Class A Common Stock	11,400	$3.98	$45K

Holdings After Transaction: Class A Common Stock — 1,207,829 shares (Direct)

Footnotes (1)

1. This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2026 and every three months thereafter. This RSU vested immediately upon the grant date. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Ben R

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/06/2026		A(1)		446,279	A	$0	1,207,829	D
Class A Common Stock	02/06/2026		A(2)		24,254	A	$0	1,232,083	D
Class A Common Stock	02/06/2026		F(3)		11,400	D	$3.98	1,220,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2026 and every three months thereafter.

2. This RSU vested immediately upon the grant date.

3. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RXRX’s CFO report on February 6, 2026?

On February 6, 2026, RXRX’s CFO Ben R. Taylor reported receiving 446,279 Class A restricted stock units and 24,254 restricted stock units that vested immediately. These equity awards increased his direct beneficial ownership in Recursion Pharmaceuticals’ Class A Common Stock.

How many RXRX shares does the CFO own after the reported Form 4 transactions?

After the reported transactions, RXRX’s CFO directly beneficially owned 1,220,683 shares of Class A Common Stock. This figure reflects both new restricted stock unit grants and shares withheld by the issuer to cover tax obligations tied to RSU settlement.

How do the newly granted RSUs to RXRX’s CFO vest over time?

The 446,279 RSUs granted to RXRX’s CFO vest in one-sixteenth increments starting May 15, 2026, then every three months thereafter. This creates a structured, time-based vesting schedule that ties a significant portion of his compensation to ongoing service.

Were any RXRX shares sold by the CFO in this Form 4 filing?

The filing shows 11,400 shares at $3.98 classified under code F, representing shares withheld by the issuer for tax obligations on RSU settlement. This reflects tax withholding, not an open-market sale initiated by the CFO.

What does transaction code “A” mean in the RXRX CFO’s Form 4?

Transaction code “A” in the CFO’s Form 4 indicates shares acquired, here via restricted stock unit grants. He received 446,279 time-vested RSUs and 24,254 RSUs that vested immediately, both at a stated price of $0 per share.

What role does Ben R. Taylor hold at Recursion Pharmaceuticals (RXRX)?

Ben R. Taylor is the Chief Financial Officer of Recursion Pharmaceuticals. The Form 4 confirms his status as an officer, not a director or 10% owner, and reports equity compensation and related tax withholding events in the company’s Class A Common Stock.